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Abstract: Nuclear receptor PPARγ affects lipid metabolism in several tissues, but its role in intestinal
lipid metabolism has not been explored. As alterations have been observed in the plasma lipid profile
of ad libitum fed intestinal epithelium-specific PPARγ knockout mice (iePPARγKO), we submitted
these mice to lipid gavage challenges. Within hours after gavage with long chain unsaturated
fatty acid (FA)-rich canola oil, the iePPARγKO mice had higher plasma free FA levels and lower
gastric inhibitory polypeptide levels than their wild-type (WT) littermates, and altered expression of
incretin genes and lipid metabolism-associated genes in the intestinal epithelium. Gavage with the
medium chain saturated FA-rich coconut oil did not result in differences between the two genotypes.
Furthermore, the iePPARγKO mice did not exhibit defective lipid uptake and stomach emptying;
however, their intestinal transit was more rapid than in WT mice. When fed a canola oil-rich diet
for 4.5 months, iePPARγKO mice had higher body lean mass than the WT mice. We conclude that
intestinal epithelium PPARγ is activated preferentially by long chain unsaturated FAs compared
to medium chain saturated FAs. Furthermore, we hypothesize that the iePPARγKO phenotype
originates from altered lipid metabolism and release in epithelial cells, as well as changes in
intestinal motility.
Keywords: PPARγ; intestine; lipid metabolism
1. Introduction
The digestion of lipids starts in the oral cavity and involves lipases secreted by the lingual glands.
The process continues in the stomach, where fats become emulsified and enter the duodenum as fine
lipid droplets. There, they are further emulsified, micellized, and processed by bile acids and the
pancreatic juice, eventually resulting in the formation of monoglycerides, free glycerol, and free fatty
acids (FFAs) [1,2]. CD36 and various Fatty acids biding proteins (FABPs) facilitate long chain fatty
acid (LCFA) transport across the apical membrane of enterocytes [3,4]. After entering enterocytes,
FFAs and glycerol arrive at the crossroads of several pathways; they can be metabolized within
mitochondria or be transported to the endoplasmic reticulum, where several enzymes, including
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GPAT, AGPAT, Lipin, and DGAT, catalyze the formation of triglycerides (TGs) [5–7]. The resulting
TGs bind to the microsomal triglyceride transport protein (MTTP), which assists in the generation of
chylomicrons in the endoplasmic reticulum [8,9]. Depending on the cellular lipid load, TGs can also be
temporarily stored in cytosolic lipid droplets (CLDs) within enterocytes [10], from which they can be
released by lipases, such as ATGL and HSL, and further trafficked to chylomicrons [11,12]. Afterwards,
chylomicrons are transported to the Golgi complex and are secreted from enterocytes to the lymph [2].
As long chain FAs (LCFAs) go through these complex absorption, rebuilding, and secretion steps,
medium chain fatty acids (MCFAs) are processed faster and more easily. Given their lower mass,
MCFAs are hydrolyzed rapidly and more completely by pancreatic lipase than LCFAs, and do not form
micelles. In addition, their short carbon chain makes them weak electrolytes that are highly ionized at
neutral pH, which increases their solubility and accelerates their transporter-free absorption. Due to
the bias of TG-assembling enzymes in enterocytes towards FAs with chains >12 carbons, MCFAs are
not incorporated into TGs. Therefore, 95% of MCFAs are not integrated into chylomicrons, but are
directly shed into the portal vein and travel quickly to the liver as FFAs. Therefore, MCFAs reach this
organ much faster than LCFAs [13,14].
Canola oil is much appreciated by nutritionists due to its high unsaturated FA content. The oil is
composed of 71% monounsaturated fatty acids (MUFAs), 21% polyunsaturated fatty acids (PUFAs),
and only 6.3% saturated FAs [15]. Because of its plant sterol and tocopherol content, canola oil is
thought to be cardioprotective [16], and canola oil-based diets reduce plasma TG and low-density
lipoprotein cholesterol (LDL-C) levels, as well as biomarkers of coronary heart disease [17]. In contrast,
coconut oil consists mainly of saturated FAs (92%) with a high lauric acid content (47%), and also other
MCFAs (17%) [13]. Lauric acid with its 12-carbon atom chain, shares only some of the properties of
MCFAs; however, during the digestion process, it can be released faster and absorbed more rapidly
than LCFAs [13]. As a plant-derived oil, coconut oil is considered as a healthier alternative to animal
fat, but it increases total cholesterol, high-density lipoprotein cholesterol (HDL-C), and LDL-C levels
in the blood [13].
PPARs form a subfamily of the nuclear receptor family, which consists of PPARα, PPARβ/δ,
and PPARγ [18]. They are expressed in various tissues at varying levels, and the individual roles of
these receptors remain distinct. In the gastrointestinal tract, PPARα regulates the expression of genes
that are associated with FA, cholesterol, glucose, and amino acid metabolism, transport, and intestinal
motility in response to dietary lipids [19,20]. PPARβ/δ in the intestine regulates multiple processes,
including cell proliferation, differentiation [21], and lipid uptake [22]. Compared to the small intestine,
PPARγ is expressed at higher levels in the colon, where it inhibits dysbiotic Enterobacteriaceae
expansion [23]. However, in both of these sections of the intestine, PPARγ is present at relatively higher
levels in the proximal regions and its expression decreases towards the distal regions [24–27]. In the
small intestine, PPARγ is directly exposed to ligands that naturally occur in food, with its activity being
regulated by FAs, glutamine, curcumin, capsaicin, and vitamin E [28,29]. Thus, dietary composition
impacts PPARγ functions. Though much attention has been paid to the anti-inflammatory [30–37] and
anticarcinogenic role of PPARγ in the colon [38–41], and intestines in general [42], very little is known
about its function in the small intestine. In this section of the intestine, its expression and nuclear
translocation is activated during inflammation and injury [43]. We previously reported that intestinal
PPARγ regulates adipocyte energy mobilization via the sympathetic nervous system during caloric
restriction (CR) [44].
When considering that PPARγ is under-investigated in the small intestine and its importance in
lipid metabolism in other tissues [45], we assessed its role in small intestine lipid metabolism using
intestinal epithelium-specific PPARγ knockout mice. This approach is superior to antagonist treatment,
which does not allow for tissue-specific inhibition of receptor activity. Here, we present evidence that
PPARγ is preferentially involved in the metabolism of LCFAs in the small intestine.
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2. Results
2.1. PPARγ Regulates Lipid Transit but Not Uptake in Small Intestine
As we reported previously, the intestinal epithelium-specific PPARγ knockout mouse
(PPARγ∆/∆ VillinCre+/−, or iePPARγKO) does not demonstrate any easily apparent phenotype
in basic ad libitum conditions with respect to body weight, internal organ size, or plasma
markers (TGs, FFAs, glucose, and cholesterol) [44]. However, advanced lipidomics analysis
showed that plasma levels of several lipids differ in ad libitum iePPARγKO compared to
their wild-type (PPARγfl/flVillinCre−/−, WT) littermates. Sphingomyelins (SMs, d18:1/18:0) and
phosphatidylethanolamines (PEs, 36:0) were underrepresented in plasma from iePPARγKO as
compared to WT mice (Figure 1a), whereas the concentrations of TGs (53:0) and several types of
phosphatidylcholines (PCs) were higher in plasma from iePPARγKO mice than WT mice. In general,
saturated FAs containing lipids were less abundant and unsaturated FAs occurred at higher
concentrations in iePPARγKO when compared to WT mice. Choline is an essential component
of PC; it is also essential for bile acid homeostasis and plays a role in the lipid uptake process.
These observations suggested the involvement of PPARγ from the intestinal epithelium in lipid uptake
and/or metabolism in this tissue.
Figure 1. PPARγ does not affect lipid uptake, but regulates intestinal transit. (a) Blood was collected
from mice fed ad libitum and plasma lipid composition analyzed (n = 5). (b) Lipid uptake was
quantified by recording the radioactive tracer uptake (3H-triolein) in the duodenal epithelium 30 min
after labeled oil gavage (wild-type (WT) n = 8, KO n = 12). (c) Following 24 h incubation with the
indicated compounds, fluorescent fatty acids (FAs) were added to each well and uptake by Caco-2 cells
measured over 2 h (n = 3). (d) WT and iePPARγKO mice were gavaged with FITC-dextran in canola oil
and the fluorescence in the stomach and (e) small intestine measured. For the intestine, the geometric
center was quantified 30 min after gavage (WT n = 12, KO n = 10). The Student’s t-test was performed
for (a,b,d,e). For (c), one-way ANOVA with a Bonferroni post-hoc test was applied. Data are presented
as means ± SEM (standard error of mean). * p < 0.05.
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To characterize the role of the intestinal PPARγ, we performed a lipid uptake test in the small
intestine in iePPARγKO mice. In animals that were gavaged with a mix of canola oil and 3H-triolein,
the amount of 3H-tracer taken up by the intestinal epithelium within 30 min after gavage did not differ
between iePPARγKO and WT mice (Figure 1b). In analogous in vitro experiments, Caco-2 cells were
treated with various agonists and antagonists of the different PPAR isotypes and were incubated with
fluorescently labeled FAs. Only the agonist specific for PPARβ/δ, GW501516, clearly increased FA
uptake (Figure 1c). In contrast, rosiglitazone, an agonist of PPARγ, and WY14634, a strong agonist
of PPARα, which also weakly activates PPARβ/δ and PPARγ, did not significantly affect FA uptake.
Furthermore, GW9662, an antagonist of all three PPAR isotypes, had no significant effect on FA uptake.
Next, we performed a gastrointestinal transit assay using fluorescently labeled FAs. Stomach emptying
activity was not affected by the absence of PPARγ (Figure 1d). However, the assay revealed an increased
intestinal transit speed in iePPARγKO compared to WT mice (Figure 1e). We conclude that although
PPARγ does not affect lipid uptake in the intestinal epithelium, it regulates intestinal transit.
2.2. Long-Term Canola Oil Diet Results in Modest Body Composition Changes in iePPARγKO Compared to
WT Mice
In order to disclose an iePPARγKO phenotype, we submitted the iePPARγKO mice to an 18-week
feeding with different high-lipid diets. The animals were fed a standard high-fat diet (HFD; 60% energy
from mixed fat sources) and two fat-rich diets with 45% energy from lard or canola oil. The latter
two were set at 45% energy from fat because it was the maximum possible percentage at which the
use of liquid canola oil still allowed for the production of solid food pellets. Control groups were fed
standard chow containing 4.5% energy from fat, mostly of soy and sunflower origin. The samples
were collected in the late morning following a 2 h fast during the resting/non-eating phase to avoid
acute fat/oil effects as studied below. The animals fed HFD presented with the highest body weight
gain, followed by the canola and lard diet groups when compared to the control animals (Figure 2a).
However, only the weight increase of iePPARγKO mice fed the HFD was significant. All mice fed fat
diets (HFD, lard, and canola) consumed less food than the control mice (Figure S1a). Interestingly,
there were no significant differences in final body weight and food intake between iePPARγKO and
WT mice in any of the four groups (Figure 2a and Figure S1a). Mice fed a HFD or lard diet presented
elevated VO2 when compared to control mice (Figure S1b). Canola oil-fed mice exhibited a similar
trend, but did not reach significance. Respiratory exchange ratio (RER) was reduced in all of the mice
that were consuming fat diets (Figure S1c). No differences were noted for VO2, VCO2, RER, or heat
release between iePPARγKO and WT mice (Figure S1b–e).
Gene expression analysis revealed that PPARγ expression in the intestinal epithelium of WT mice
was not significantly modified by the fatty diets as compared to the control diet (Figure 2b). Among the
genes whose expression in the intestine was affected by canola oil gavage, only Fxr was downregulated in
iePPARγKO compared to WT mice after the 18-week canola oil diet (Figure 2c). Further perusal of the
expression of FXR target genes, such as Fabp6, Nr0b2, and Fgf15, did not reveal significant changes, not
least because of relatively high variability in expression. A trend of downregulation in the iePPARγKO
epithelium was observed for the PPAR-regulated genes Atgl, Dgat2, and Tip47. Furthermore, canola oil diet
did not trigger differences between iePPARγKO and WT mice in regards to plasma TG, FFA, cholesterol,
and glucose levels (Figure 2d). In the oral glucose tolerance test (OGTT), mice that were fed fatty diets had
significantly higher glucose plasma levels than control mice (Figure 2e and Figure S1f). Interestingly, mice
that were fed a canola diet had higher glucose levels than HFD-fed mice. No differences in plasma glucose
levels were found between iePPARγKO and WT mice at any of the time points of the OGTT for any diet.
Similarly, liver size was comparable between the two genotypes (Figure S1g).
As expected, the mice that were fed fat diets had increased relative epididymal, subcutaneous
abdominal, and dorsal white adipose tissue (WAT) weight when compared to control mice, with HFD
mice having the highest amount of WAT (Figure 2f) and the canola oil diet-fed WT mice the lowest.
The iePPARγKO mice fed a canola diet exhibited a trend towards heavier fat pads for all three of the diets
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tested and increased total body fat mass compared to their WT littermates, but the difference was not
significant. EchoMRI confirmed the trend towards increased total body fat mass in canola oil-fed animals
(Figure 2g) and revealed a significant decrease in the lean mass of iePPARγKO vs. WT canola diet mice
(Figure 2h). Expression of Acc and Fas in the WAT of mice consuming the canola diet was decreased as
compared to control mice (Figure 2i), but no difference was detected between iePPARγKO and WT mice.
Thus, a canola oil diet increased the fat mass in iePPARγKO mice when compared to WT mice and resulted
in a difference in body mass composition between the two genotypes. Furthermore, the effect on gene
expression in the duodenum of these animals fed canola oil for 18 weeks was less than that observed with
acute canola oil gavage (see below).
Figure 2. Long-term exposure to canola oil triggers mild body composition changes in iePPARγKO
vs. WT mice. (a) Body weight of mice fed chow, high fat diet (HFD), lard diet, or canola oil diet
(n = 7–10). (b) The relative mRNA expression levels of PPARγ and (c) lipid metabolism-associated
genes in the duodenal epithelium were assayed by RT-qPCR (n = 9–18). (d) Concentration of TGs, FFAs,
cholesterol, and glucose in plasma of mice fed chow and canola diet (n = 7–12). (e) Mice were submitted
to oral glucose tolerance test (OGTT) and their plasma glucose levels monitored over 2 h (n = 5–9).
(f) Weight of epididymal white adipose tissue (eWAT), subcutaneous abdominal WAT (sWAT abb),
and subcutaneous dorsal WAT (sWAT dors) presented as % of total body weight (n = 8–10). (g) Total
body fat and (h) lean mass were estimated using EchoMRI (n = 8–10). (i) Relative mRNA expression
levels in epididymal WAT from chow and canola fed mice were measured using RT-qPCR (n = 8–10).
One-way ANOVA followed by the Bonferroni post-hoc test was used to compare the experimental
groups in (b,d,f,i). The two-tail Student’s t-test was applied to verify significance (p < 0.05) in (a,c,e,g,h).
* p < 0.05 for canola iePPARγKO vs. canolaWT, a significantly differ from Chow WT, b significantly
differ from Chow KO. Data are presented as mean ± SEM.
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2.3. PPARγ Affects Lipid Metabolism in Duodenal Enterocytes
As the long-term lipid challenge with canola oil disclosed a mild iePPARγKO phenotype,
we challenged iePPARγKO and WT mice with acute lipid loads via a single gavage of canola oil
(5 µL/g body weight), which is very rich in long chain unsaturated FAs, following an overnight
fast. In WT animals, plasma TG and FFA levels were maximal after 2 h, with lower levels already
at 3 h. In iePPARγKO mice, TG levels were still increased and FFAs remained higher at 3 h with
significant differences from WT mice (Figure 3a,b). These results suggest that PPARγ in the intestinal
epithelium impacts the processing of these molecules in the small intestine. WT and iePPARγKO mice
that were gavaged with the same volume of coconut oil, which is very rich in saturated MCFAs, did
not exhibit differences in plasma TGs or FFAs, which were highest at 3 h (Figure 3a,b), but TGs were
significantly lower than after gavage with canola oil (Figure 3a). Plasma levels of total cholesterol, HDL,
and glucose were similar in iePPARγKO and WT mice after either of the two oil gavages (Figure S2a,b).
These results suggest that PPARγ selectively affected the intestinal processing of unsaturated LCFAs,
but did not impact that of saturated MCFAs.
Because PPARγ is a transcription factor, we assessed whether the above observations result from
changes in gene expression in the intestinal epithelium due to oil gavage, and whether tissue-specific
deletion of PPARγ affects them. As PPARγ is expressed at higher levels in the proximal parts of the small
intestine [24,27], we measured the mRNA levels in the duodenum. It noteworthy that the deletion of
PPARγ did not significantly affect the expression of PPARα and PPARβ/δ, which could have impacted
the results (Figure S2e). In WT mice, canola oil gavage stimulated the expression of Gip and Secretin after 2
and 3 h, respectively, whereas the expression of Cck (cholecystokinin) and Dpp4 (dipeptidyl peptidase-4)
was not affected (Figure 3c, Table S1). When compared to WT, Cck, Dpp4, and Secretin, expression was
reduced in the iePPARγKO duodenum (Figure 3c, Table S1). Plasma gastric inhibitory polypeptide (GIP)
protein levels were also significantly diminished in iePPARγKO when compared to WT mice at 3 h,
and glucagon-like peptide-1 (GLP-1) at 4 h, after canola oil gavage (Figure 3d).
Canola oil gavage resulted in the stimulation of several genes of lipid metabolism in the duodenum
of WT mice 2 and/or 3 h after gavage (Figure 3e and Figure S2c,e and Table S1). Importantly, the gene
expression profiles differed between the WT and iePPARγKO duodenum (Figure 3e and Figure S2c,d,
Table S1). In iePPARγKO mice, the genes stimulated in WT mice were expressed at lower levels 2 and/or 3
h after gavage (Figure 3e and Figure S2d, Table S1). Moreover, in iePPARγKO mice some of the genes were
initially downregulated at 2 h compared to 0 h. Among the altered transcripts were those encoded by genes
associated with lipid uptake (Cd36), TG synthesis (Dgat2, Agpat9), FA metabolism (Acot11, Fasn, Mlysd), FA
transport to mitochondria (Cact), lipid droplet formation (Hsl, Atgl, Tip47), and chylomicron production
(Mttp) (Figure 3e). Notably, the mRNA levels of Fxr were affected, suggesting a possible impact of PPARγ
on bile acid signaling. Among the genes that were not influenced by the absence of intestinal PPARγ were
those associated with cholesterol and lipid absorption (Abca1, Abcg5, Ppap2a), lipid metabolism (Lcad, Cpt-1),
lipoprotein composition (ApoAIV, ApoB, Vti1A), mitochondrial ATP production (Atp5e), and mitochondrial
respiratory chain (Uqcr2). Notably, the Pparγ mRNA level was not altered in WT mice after canola oil
gavage (Figure S2f). Importantly, the level of mRNA of Pparα was downregulated in iePPARγKO 2 h
after the gavage (Figure S2e). However, the expression pattern of Pparα and β/δ did not differ between
iePPARγKO and WT mice at any time point following the gavage (Figure S2e), which indicates that their
action in lipid metabolism is independent of Pparγ.
In contrast to the above results, coconut oil gavage did not trigger differences in intestinal
epithelium gene expression between iePPARγKO and WT mice, with the exception of Tip47, which is
involved in the biogenesis of lipid droplets (Figure 3f) and shares a significant homology with the
other members of this family, including perilipin and adipophilin [46].
Interestingly, Npy (p = 0.03), which is associated with the regulation of metabolism and behavior,
and Mchr1 (p = 0.05) whose product is thought to have a number of functions, including the
regulation of appetite [47,48], were down- and slightly up-regulated, respectively, in the hypothalami of
iePPARγKO compared to WT mice 3 h after canola oil gavage (Figure 3g). Meanwhile, the expression of
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other hypothalamic appetite-related genes (Hpmr, Hcrtr1, Mc4r, Npbw1) was not affected in iePPARγKO
mice after canola oil gavage (Figure S2g).
Collectively, these results show that PPARγ in enterocytes is activated by canola oil to specifically
control pathways that are connected with FA metabolism and mitochondrial function, and possibly affect
some hypothalamic functions. In contrast, PPARγ activity appears to not be influenced much by saturated
MCFAs. This finding is in line with the previously reported preference of PPARγ for PUFAs as ligands [49].
Figure 3. Canola oil gavage triggers differences in lipid metabolism signaling between iePPARγKO
and WT mice. (a) Triglyceride (TG) and (b) free fatty acid (FFA) levels were measured in plasma after
canola (n = 6) and coconut (n = 5–6) oil gavage. (c) Applying RT-qPCR, the relative mRNA expression
levels in the duodenal epithelium were analyzed for intestinal hormones. (d) Plasma concentrations of
insulin, GLP-1, and GIP were measured for WT and iePPARγKO mice gavaged with canola oil (n = 6–7).
(e) The relative mRNA expression levels were quantified for lipid metabolism-associated genes in
the duodenal epithelium of animals gavaged with canola oil and (f) coconut oil (n = 5–6) and (g) for
hunger-related genes in the hypothalami of canola oil gavaged WT and iePPARγKO mice (n = 6–10).
* Significant differences between iePPARγKO and WT mice. # p < 0.05; ## p < 0.08. a Significant
differences between the labeled group and 0 h WT canola, b 0 h KO canola, c 0 h WT coconut, and d 0 h
KO coconut. One-way ANOVA with a Bonferroni post-hoc test was applied for statistical analysis.
Error bars depict the standard error.
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3. Discussion
A previous investigation of iePPARγKO mice fed a chow diet when compared to WT mice did
not reveal an easily recognized phenotype [44]. Here, a more in-depth plasma analysis revealed
differences in circulating lipids, particularly the PC fraction. We also found that, after long-term
exposure to a canola oil-rich diet (18 weeks), the iePPARγKO mice had reduced relative lean mass
compared to WT animals, which correlated with a trend of higher fat mass, in line with the previously
reported adipose tissue dysregulation in these animals under CR [44]. Furthermore, after canola
oil gavage, we observed changes in plasma TG and FFA levels between iePPARγKO and WT mice.
These modifications in circulating lipids were not due to faulty lipid uptake, but were correlated with
increased intestinal transit in iePPARγKO mice, and, importantly, iePPARγ-dependent changes in
enterocyte gene expression. The modulated genes are associated with lipid metabolism, mitochondrial
functions, and gut hormones.
As mentioned above, the plasma levels of several PCs were increased in iePPARγKO mice.
In humans, PCs are derived mostly from bile acids (10–20 g/day), but also from the diet (1–2 g/day) [2].
If this also prevails in rodents, the level of PCs in plasma may reflect changes in bile acid metabolism.
The loss of Fxr upregulation after canola oil gavage and canola diet in iePPARγKO mice also suggests
that bile acid metabolism may be affected by the absence of PPARγ in the intestinal epithelium.
Although there was a trend for a lower expression of several FXR target genes in iePPARγKO mice,
the difference from WT did not reach significance. Therefore, a possible alteration of the role of FXR
in the iePPARγKO phenotype remains to be investigated more in-depth in the future. Choline and
its metabolites are needed for the structural integrity of cell membranes and their signaling roles,
cholinergic neurotransmission, and participation in the S-adenosylmethionine (SAMe) synthesis
pathways. As PCs are the predominant type of phospholipids in the intestinal lumen and were
increased in iePPARγKO mice, we evaluated whether intestinal lipid uptake was perturbed in
iePPARγKO mice. Although iePPARγ did not modify the amount of lipid that was taken up, canola
oil gavage led to differences in plasma lipid levels between WT and iePPARγKO mice, which is
in line with alterations in epithelial gene expression in the latter. The persistence of high plasma
TG and FFA levels 3 h after gavage may suggest a modified intestinal transit time, release from the
epithelium, or clearance from the bloodstream. The expression of several genes in the intestinal
epithelium was reduced in the absence of iePPARγ. Together, these genes are implicated in all of
the processes of lipid metabolism in enterocytes (Figure 4), including lipid transport (Cd36 [50–53]),
lipolysis (Hsl [50,52,54,55], and Atgl [51,55,56]), and various lipid metabolism pathways (Cact [57],
Fasn [58,59], Mlycd [60], Dgat2 [50,52,55,59], and Agpat9 [51,55,61]). Interestingly, Acot 11 (hydrolysis of
various coenzyme A esters), Tip 47 (lipid droplet formation), and Mttp (chylomicron assembly) were
previously not associated with PPARγ in any tissue. In addition, Tip 47 was differentially expressed
between the two phenotypes after both canola oil and coconut oil gavage, suggesting that coconut oil
contains some FAs that may moderately affect some PPARγ pathways. In the future, an investigation
at the protein level (expression, posttranslational modifications) will further the present study.
Previously, we demonstrated that the intestinal PPARγ negatively affects the expression of
incretins and their plasma levels during CR [44]. Here we showed that, after canola oil gavage,
the mRNA and plasma levels of incretins are reduced in iePPARγKO compared to WT mice,
which demonstrates the different roles of PPARγ in intestinal hormone synthesis in different nutritional
contexts. Interestingly, based on previously published findings by others [62,63], this downregulation
of GIP, CCK, or secretin levels in iePPARγKO mice may explain the difference in intestinal passage time,
which was increased in these mice. When considering that the lipid load increases gut motility [64],
we hypothesize that fat may act through PPARγ to regulate intestinal transit, a function that has also
been attributed to PPARα [19]. Such a putative role of PPARγ remains to be studied, as we have
observed slightly accelerated transit in the iePPARγKO mice. Interestingly, gavage with saturated
fat-rich coconut oil had much weaker effects than canola oil. This is very much in line with PPARγ
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having a preference for PUFAs as ligands, which are enriched in canola oil, over saturated FAs as
ligands, which are abundant in coconut oil [28,29,49].
Interestingly, an 18-week-long canola oil feeding with sampling after 2 h fast during the resting
non-feeding time did not produce the same clear effects as acute gavage. These observations suggest
that the feeding time and the type of fats in the food directly regulate PPARγ activity in the intestinal
epithelium. Alternatively, long-term fat feeding may change the lipid uptake and processing in
the intestine [65], and, thus, the iePPARγKO phenotype may be attenuated under this condition.
Nonetheless, we observed an effect of long-term canola oil feeding with a change in the ratio
between lean and fat body mass in iePPARγKO mice when compared to WT mice. This difference
in body composition may originate from a faulty metabolism of lipids in the intestine, as discussed
above. Alternatively, canola-activated PPARγ could also lead to a similar effect on lipid release
from WAT via PPARγ-dependent sympathetic nervous system signaling, as described previously [44].
The absence of this signal would result in fat retention in the adipose tissue, which is in line with our
present observations.
Oils with different FA composition causing different phenotypes in iePPARγKO implies that
intestinal PPARγ specifically regulates complex pathways under the influence of LCFAs, which are
enriched in canola oil as naturally occurring agonists of PPARγ [28,29]. Our results suggest that
consumption of oils rich in PPARγ agonists may improve the efficiency of lipid metabolism in the
intestine and also impact the lean/fat mass ratio. In conclusion, we hypothesize that intestinal
epithelium PPARγ affects lipid processing and/or the storage in enterocytes and adipose tissue, and its
deletion would result in delayed trafficking in enterocytes and, possibly as described for CR [44], fat
retention in adipose tissue.
Figure 4. Model of lipid processing regulation by PPARγ in enterocytes. Red font indicates genes
whose upregulation is lost or expression is reduced in enterocytes of iePPARγKO mice after canola oil
gavage. Following intestinal digestion, FAs and glycerol are absorbed by enterocytes. Medium chain
FAs (MCFA) travel through the enterocyte directly to blood (portal vein) (dashed arrow) and are
transported to the liver as free FAs. Long chain FAs (LCFAs) are taken up by the enterocytes with the
assistance of transporter proteins (CD36 and FATP). FAs are trafficked to mitochondria, where they are
catabolized, or to the endoplasmic reticulum (ER), where there serve as substrates for TG assembly.
Depending on the lipid load, TGs can be temporarily stored in cytoplasmic lipid droplets (CLD) or
incorporated into chylomicrons and secreted into the lymph.
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4. Materials and Methods
4.1. Mouse Handling
All of the animal experiment protocols were approved by the Vaud Cantonal Authority (SCAV
24735; authorization: VD 2440.3; 01 April 2015), Switzerland. As described previously [44],
the intestinal epithelium-specific PPARγ knockout mouse was obtained by crossing floxed Pparγ
(PPARγfl/fl) mice with mice expressing the Cre recombinase transgene under control of the villin
promoter (VillinCre+/−). The offspring PPARγ∆/∆ VillinCre+/− mice with targeted disruption of
PPARγ in the intestinal epithelium were named iePPARγKO mice and were used in parallel with
littermate control PPARγfl/fl (WT) mice with the same genetic background. Male mice were kept under
a 12-h light/12-h dark cycle in standard housing cages. The animals were fed a standard laboratory
diet, unless otherwise stated, and housed with free water access. For the oil gavage experiments, 10 to
12-week-old mice were fasted overnight. The next morning, the mice received 5 µL canola or coconut
oil (Sigma-Aldrich, Buchs, Switzerland) per gram of body weight via gavage. The animals were
dissected directly after overnight fasting or 2 and 3 h after oil gavage. The mice were euthanized using
CO2 and blood was drawn by cardiac puncture. The blood was mixed with 2% aprotinin-EDTA (Sigma,
Mendota Heights, MN, USA) and DPPIV inhibitor (Merck, Kenilworth, NJ, USA), centrifuged for
10 min at 8000× g, and plasma frozen. Epididymal WAT, subcutaneous abdominal WAT, dorsal WAT,
and liver weight were recorded. Duodenum scrapings and hypothalami were collected. All tissues
were frozen in liquid nitrogen and stored at −80 ◦C until use.
For the diet experiments, five-week-old mice were randomly assigned to one of the diets: chow
containing 4.5% energy from fat, mostly of soy and sunflower origin (Diet 3436, Provimi Kliba AG,
Penthalaz, Switzerland); HFD with 60% kcal from fat in which the main fat source was lard (D12492
OpenSource Diets, Research Diets, New Brunswick, NJ, USA); or, HFD with 45% kcal fat from canola
oil or lard (custom made modified D12451 diets, Research Diets). Body weight and food intake were
measured weekly. After 15 weeks feeding with these diets, metabolic parameters (VO2, VCO2, heat
production) and locomotor activity were monitored for three days using the Comprehensive Lab
Animal Monitoring System (CLAMS, Columbus Instruments, Columbus, OH, USA). After 16 weeks
of feeding with the control and HFDs, mice were submitted to the OGTT. Briefly, mice were fasted
overnight, placed in single cages, and the first blood samples drawn from the tail. Next, the mice
were gavaged a glucose solution and received the equivalent of 3 mg of glucose per gram body
weight. Blood glucose levels were monitored after 15, 30, 60, 90, and 120 min. After 17 weeks of the
diet, bedding maintained in the cage for 24 h was collected. Feces were separated from the bedding,
dried, and fecal energy load measured using direct calorimetry (IKA-Kalorimeter C2000; IKA®-Werke
GmbH & Co. KG; Staufen, Germany). Afterwards, the mouse body composition was measured
under anesthesia using an EchoMRI whole-body composition analyzer (EchoMRI, Huston, TX, USA).
After the EchoMRI, the mice were given 1 week to recover and then dissected following the procedure
described above between 9 a.m. and 11 a.m. following 2 h fasting.
4.2. Intestinal 3H-Triolein
After overnight fasting, mice received 200 µL canola oil containing 15 µCi 3H-triolein by gavage
and sacrificed 30 min later. Blood was removed by perfusing the heart for 3 min with PBS. The intestinal
lumina was flushed four times with 5 mM taurocholate, the small intestine divided into three equal
segments (proximal, medial, and distal), and the segments were dissolved in SolvableTM (Perkin Elmer,
Courtaboeuf, Villejust, France) overnight at 60 ◦C and incubated in scintillation fluid (Betaplate Scint,
Perkin Elmer, Waltham, MA, USA). The radioactivity in each intestinal segment was measured by a
liquid scintillation analyzer.
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4.3. Gastric Emptying and Intestinal Motility
Overnight-fasted mice were gavaged with 200 µL of 5 mmol/L FITC-dextran (70 kDa
FITC-dextran, Sigma) in canola oil and sacrificed 30 min later. Animals’ small intestines were divided
into 10 equal parts. The stomach and each part of the intestine was opened longitudinally, vortexed
thoroughly with PBS, and centrifuged at 1200 rpm for 5 min. The intensity of fluorescence in the
supernatant was measured. The geometric center used as an index of intestinal transit was calculated
as the sum of the % fluorescence per segment × segment number [66].
4.4. RT-qPCR
RNA was isolated from intestinal scrapings using the RNeasy mini kit (Qiagen, Hombrechtikon,
Switzerland). Samples were thawed in lysis buffer, disrupted using a syringe and needle, and processed
following the manufacturer’s recommendations. RNA was extracted from adipose tissue and the
hypothalamus using the RNeasy Lipid Tissue mini kit (Qiagen). SuperScript® II Reverse Transcriptase
(Thermo Fisher Scientific, Lausanne, Switzerland) and random primers (Promega, Madison, WI, USA)
were used for the reverse transcription step for all of the samples. Quantitative real-time PCR (qRT-PCR)
reactions were carried out using the Applied Biosystems 7900HT (Thermo Fisher Scientific) with the
SYBR green PCR Master Mix (Applied Biosystems, Thermo Fisher Scientific). Primers used for
qRT-PCR are listed in Table S2.
4.5. Plasma Analysis
Serum (10 µL) samples were diluted with 0.9% NaCl (10 µL) buffer. All of the samples were spiked
with an internal standard (10 µL). Subsequently, the samples were extracted with chloroform: methanol
(2:1) solvent (100 µL), homogenized with a glass rod (serum) at 4 ◦C by adding two zirconium oxide
grinding balls, vortexed (1 min), incubated at room temperature (1 h), and centrifuged at 5590× g for
3 min. An aliquot of the separated lower phase (60 µL) was mixed with a labeled standard mixture
(three stable isotope-labeled reference compounds; 10 µL) and 0.5–1.0 µL injection used for the analysis.
The sample order for analysis was established by randomization. Lipid extracts were analyzed on a
Q-ToF Premier mass spectrometer (Waters, Milford, MA, USA), and combined with an Acquity ultra
performance liquid chromatograph (UPLC/MS).
Plasma glucose, lipid, and cholesterol levels were measured using a Hitachi chemistry analyzer
(Roche Diagnostics, Basel, Switzerland), according to the manufacturer’s instructions.
Plasma insulin, GLP-1, and GIP concentrations were estimated using Bio-Plex® (Luminex Corporation,
Austin, TX, USA).
4.6. Cell Culture
Caco-2 cells were maintained in high glucose DMEM supplemented with 10% fetal bovine serum,
100 U/mL penicillin and 100 U/mL streptomycin (all from Sigma-Aldrich) in a humidified atmosphere
of 5% CO2 at 37 ◦C. Cells were cultured for 10 days after reaching confluence. Rosiglitazone, WY14634,
GW501516, and GW9662 (all from Sigma) were added to the culture at final concentrations of 10 µM for
24 h. Control cells received the DMSO (Sigma) vehicle or no treatment. Afterwards, BODIPY-labeled
fatty acids (QBT Fatty Acid Uptake Assay Kit, Molecular Devices, Wokingham, Berkshire, UK) were
added to the culture and fluorescence measured over 2 h. The results are presented as area under
the curve.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/12/2559/s1.
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